PRIMA Launches in Europe: A New Approach to Restoring Central Vision in Geographic Atrophy.

Science Corporation has launched PRIMA in Europe, a retinal implant designed to restore central vision in people with geographic atrophy due to age-related macular degeneration. The launch follows PRIMA receiving CE marking under the European Union Medical Device Regulation, enabling commercial availability across 30 European countries. The first implant is expected in Germany, with regulatory review ongoing in the United States.PRIMA represents an important step towards restoring visual functions such as reading letters, numbers and words. Science Corporation

Addressing Vision Loss Caused by Geographic Atrophy.

Geographic atrophy is an advanced form of dry age-related macular degeneration. It progressively damages the photoreceptors and retinal cells responsible for central vision. As the condition advances, patients can lose the ability to read, recognise faces and complete everyday tasks independently. Existing treatments may help slow the progression of geographic atrophy, but they do not restore vision that has already been lost.PRIMA takes a different approach. Instead of targeting the underlying disease process, the system is designed to replace some of the visual function lost when photoreceptors in the centre of the retina are damaged.

How Does the PRIMA Retinal Implant Work?

The PRIMA system combines a tiny wireless photovoltaic implant with a pair of specialised glasses. A camera integrated into the glasses captures the patient’s surroundings. The visual information is processed and projected as patterned near-infrared light onto the implant, which is positioned beneath the atrophic area of the retina. The implant contains 378 photovoltaic pixels that convert this light into electrical pulses. These pulses stimulate the remaining retinal cells, allowing visual signals to travel through the optic nerve and be interpreted by the brain. The system also includes digital magnification and contrast features to help patients distinguish letters, shapes and other visual information. Because the implant is photovoltaic, it does not require cables or an internal power supply. PRIMA

Clinical Trial Results.

The clinical evidence supporting PRIMA’s European approval came from a prospective, multicentre study involving 38 patients across 17 clinical sites in five countries. At 12 months, the study reported:

• An average improvement of 25.5 ETDRS letters, equivalent to more than five lines on a standard visual acuity chart.
• 84% of patients reported being able to read letters, numbers and words using PRIMA.
• 80% achieved an improvement of at least 10 ETDRS letters.
• No decline in mean existing natural vision following placement of the implant beneath the atrophic macula.

These findings suggest that PRIMA may provide meaningful artificial central vision while preserving the patient’s remaining natural peripheral vision. The results were published in the New England Journal of Medicine. Ophthalmology Times Europe. The results should be considered within the context of a relatively small, single-arm clinical study. Patients also underwent specialist surgery and a structured vision-rehabilitation programme, both of which will be important considerations as the technology moves into wider clinical use.

What Does the CE Mark Mean for PRIMA?

PRIMA’s CE mark enables the system to be commercially introduced across 30 European countries. However, regulatory approval is only one part of achieving meaningful patient access. Science Corporation has said that country-specific reimbursement applications and clinical site activations are now underway. The company expects the first commercial implant to take place in Germany. Introducing the technology will require certified clinical centres, trained vitreoretinal surgeons and specialist rehabilitation teams. It will also depend on effective reimbursement pathways and clear patient-selection processes.PRIMA remains investigational outside the EU and the European Economic Area. In the United States, the system has received FDA Breakthrough Device and Humanitarian Use Device designations, but it has not yet received approval for commercial distribution.

A Potential Turning Point for Geographic Atrophy Care.

PRIMA represents a potentially significant change in the direction of geographic atrophy innovation. Much of the progress within the field has focused on slowing disease progression. PRIMA introduces a different clinical ambition: restoring a degree of functional central vision after photoreceptors have already been lost. Its European launch also demonstrates how ophthalmology is increasingly converging with neural engineering, wearable technology, advanced image processing and vision rehabilitation. Commercial success will depend on more than the performance of the implant itself. Science Corporation and its clinical partners will need to develop the infrastructure, training, reimbursement and patient-support pathways required to deliver the technology safely and consistently. This will create demand for multidisciplinary expertise across clinical affairs, market access, professional education, surgical training, commercial leadership and post-procedure rehabilitation.

What Comes Next for PRIMA?

The immediate priority will be the activation of European treatment centres and the completion of the first commercial procedures in Germany. The industry will also be watching how PRIMA performs outside the controlled clinical-study environment, including how effectively patients can access treatment, complete rehabilitation and integrate artificial central vision into everyday life. Progress with the FDA will determine whether the system can move towards commercial availability in the United States. While further real-world evidence will be important, PRIMA’s European launch is a major milestone for retinal technology, and a significant step towards a future in which geographic atrophy care could move beyond slowing vision loss to restoring meaningful visual function.